Compass Therapeutics : Corporate Presentation

Corporate Presentation

October 2023

DISCLAIMER

This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation includes forward-looking statements regarding our drug candidates, the timing and outcome of regulatory decisions, future availability of clinical trial data, our collaborations for our product candidates and the maintenance of those collaborations, business and results from operations, and other matters. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including without limitation: that our drug candidates do not advance in development or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates that have completed early-stage trials do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; our ability to protect our intellectual property rights, and unexpected costs, charges or expenses that reduce cash runway. Our pipeline programs are in various stages of pre-clinical and clinical development, and the process by which such pre-clinical or clinical therapeutic candidates could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. These and other risks and uncertainties that we face are described in our most recent Annual Report on Form 10-K, and in other filings that we make with the Securities and Exchange Commission from time to time. We undertake no obligation to update forward-looking statements as a result of new information or otherwise.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This presentation concerns drugs that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

2

Corporate Highlights

We are a clinical stage biotech company developing antibody therapeutics for cancer

LEAD ASSETS

CORE SCIENCE

RESOURCES

CTX-009: DLL4 x VEGF-A bispecific antibody

CTX-471: CD137 agonist antibody

CTX-8371:PD-1 x PD-L1 bispecific antibody

StitchMabs™ platform designed to identify synergistic bispecific antibodies Common Light Chain technology enables multi-specificity and manufacturability Translational research

Cash runway into 2026 (Jun 2023: $169M)

Funded by leading life-science investors

~30 FTEs based in Boston, MA with experienced leadership team

3

Focused Pipeline with Multiple Value Inflection Points

Program

Target

Discovery	Lead	IND Enabling	Phase 1b	Phase 2	Next Milestone
Optimization	Pre-Clinical	Clinical	Clinical

CTX-009

DLL4 x VEGF-A

CTX-471

CD137

COMPANION-002: BTC	Top line data in U.S. H2 2024
COMPANION-003: Colorectal	Top line data in U.S. H2 2023
COMPANION-004: TBD
Initiate in U.S. H1 2024

CD137 agonist (monotherapy)

CD137 + PD-1 (combination)*

Top line data in U.S. Q4 2023

CTX-8371

PD-1 x PD-L1

Solid Tumors

Initiate Phase 1 Q4 2023

*Clinical collaboration with Merck & Co. Inc., Rahway NJ USA in combination with anti-PD-1 therapy Keytruda®

4

Leadership Team Experienced in Drug Discovery and Development

Senior Executive Team

Thomas J. Schuetz, MD, PhD	Vered Bisker-Leib, PhD, MBA	Minori Rosales, MD, PhD
Co-Founder, CEO and Director	President and COO	SVP, Head of Clinical Development

Vice Presidents

Carl L. Gordon,

Chairman of the

Board

Jon Anderman	Ian Chia, PhD	Bing Gong, PhD	Karin Herrera	Neil Lerner, CPA, MIM	James Kranz, PhD
VP, Head of Legal	VP, Business Development	VP, Protein Sciences	VP, Clinical Operations	VP, Finance	VP, CMC

5

CTX-009

DLL4 X VEGF-A bispecific antibody

Overview of CTX-009

• Bispecific antibody blocking DLL4 (Notch-1 ligand) and VEGF-A (soluble ligand)
• Does not lead to ADCC, Fc inactive
• Binds to its targets with 2:2 valency
• At 10 mg/Kg, CTX-009 has approximately the same VEGF-A capturing ability as bevacizumab

(Avastin)

• The only DLL4 X VEGF bispecific that demonstrated monotherapy activity in the clinic in colorectal and gastric cancer
• Durable responses in patients with cholangiocarcinoma seen in Phase 1b study of CTX-009 in combination with paclitaxel

7

CTX-009 - Vision and Potential

Best-in-class DLL4 x VEGF- A bispecific

Phase 2/3 nearing initiation with ongoing Phase 2 parallel development in S. Korea and China

Oncology

Has demonstrated compelling activity in the 3rd line and 4th line settings in patients with Cholangiocarcinoma, Colorectal Cancer, Gastric Cancer and Pancreatic Cancer

Could become front line therapy in multiple solid tumors

Other potential indications based on DLL4 expression such as Ovarian Cancer & Renal Cell

Ophthalmology

Potential to address AMD and DME based on mechanism

Consideration for partnership

8

CTX-009 Phase 1 Program Summary

Phase 1a: dose-escalation monotherapy study	Phase 1b: combination study with chemotherapy
N=45: Gastric, CRC, Other	N=17: 4 arms
Nine dose-escalation cohorts (0.3-17.5 mg/kg)	1.	CTX-009	10.0 mg/kg + paclitaxel
2.	CTX-009	10.0 mg/kg + irinotecan
Four dose-expansion cohorts (7.5-15 mg/kg)	3.	CTX-009	12.5 mg/kg + paclitaxel
	4.	CTX-009	12.5 mg/kg + irinotecan

Phase 1 Results

Safety: well-tolerated; MTD has not been determined

Activity: 8 PRs, 6 confirmed by RECIST in 33 advanced solid tumor patients treated

Responses as a monotherapy: colorectal and gastric

Responses in combination with chemotherapy: cholangiocarcinoma, pancreatic

Cholangio ORR= 50%; Clinical benefit rate = 75% with a median duration of response of 9.7 months

9

Phase 1a CTX-009 Monotherapy (all doses)

100

40 evaluable patients as of February 5, 2021

(All Phase 1 Patients, 0.3-17.5 mpk)

Gastric

	80	75%																																CRC
																																		Other
	60
			48%
(%)	40			40% 39%
				30%
Growth
					23%
20						15% 15% 14%	10%
							9%	9%	8%	8%	7%	7%	6%
Tumor											4%	4%	4%	3%	3%
															0%	0%	0%			10.0	5.0	12.5	7.5	1.0	2.5	7.5	10.0	12.5	15.0	10.0	12.5	10.0
0																				12.5	0.3
	0.3	0.3	12.5 12.5	0.3	2.5	12.5 17.5 12.5	5.0	7.5	7.5	5.0	10.0	15.0	2.5	15.0	12.5	1.0	12.5	12.5 1.0	15.0	17.5	5.0	-1%
		-5%	-5%
																									-9%	-9% -11%-13%
	-20																										-17%-20%
																																	-26%-27%
	-40																																		-35%-38% -40% -41%
	-60

Patient (Dosage mpk)

10